We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+25.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$697M
AUM Growth
-$38.9M
Cap. Flow
-$135M
Cap. Flow %
-19.43%
Top 10 Hldgs %
45.64%
Holding
96
New
21
Increased
21
Reduced
26
Closed
24

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$12.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.91M
3
CCCC icon
C4 Therapeutics
CCCC
+$8.29M
4
CELC icon
Celcuity
CELC
+$7.84M
5
HCA icon
HCA Healthcare
HCA
+$7.74M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$27.1M
2
UTHR icon
United Therapeutics
UTHR
+$26.9M
3
CVS icon
CVS Health
CVS
+$18.4M
4
NVST icon
Envista
NVST
+$15.7M
5
LLY icon
Eli Lilly
LLY
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.09%
2 Consumer Staples 1.8%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOCL
1
EDAP TMS S.A.
FOCL
$226M
$54.7M 7.85%
5,134,430
+244,685
+5% +$2.4M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$45.3M 6.5%
2,114,728
-387,873
-15% -$8.28M
UTHR icon
3
United Therapeutics
UTHR
$26.3B
$35.7M 5.12%
128,268
-106,591
-45% -$26.9M
BCAB icon
4
BioAtla
BCAB
$5.59M
$34.8M 5%
84,408
+16,398
+24% +$6.8M
ACLX
5
DELISTED
Arcellx
ACLX
$34.2M 4.9%
1,102,447
-137,466
-11% -$3.15M
SRDX
6
DELISTED
Surmodics
SRDX
$26.5M 3.8%
775,311
+6,833
+0.9% +$229K
VCEL icon
7
Vericel Corp
VCEL
$2.3B
$23.9M 3.43%
908,997
+534,997
+143% +$12.7M
CRL icon
8
Charles River Laboratories
CRL
$10.9B
$22.2M 3.18%
101,850
-27,250
-21% -$5.95M
IRMD icon
9
iRadimed
IRMD
$1.21B
$21.1M 3.02%
745,004
+60,314
+9% +$1.73M
ORGO icon
10
Organogenesis Holdings
ORGO
$308M
$19.8M 2.84%
7,363,063
+874,000
+13% +$2.55M
CVRX icon
11
CVRx
CVRX
$126M
$18.6M 2.67%
1,014,640
-44,400
-4% -$548K
PCVX icon
12
Vaxcyte
PCVX
$7.89B
$18.6M 2.67%
387,950
+52,300
+16% +$2.05M
CELC icon
13
Celcuity
CELC
$4.03B
$17M 2.43%
1,210,228
+766,316
+173% +$7.84M
KRYS icon
14
Krystal Biotech
KRYS
$9.88B
$14.9M 2.14%
188,217
-19,115
-9% -$1.42M
CCCC icon
15
C4 Therapeutics
CCCC
$376M
$14.4M 2.07%
2,440,843
+999,330
+69% +$8.29M
LLY icon
16
Eli Lilly
LLY
$1.07T
$14.3M 2.05%
39,100
-41,700
-52% -$14.8M
NARI
17
DELISTED
Inari Medical, Inc. Common Stock
NARI
$14.3M 2.05%
224,550
+122,942
+121% +$8.91M
EXAS
18
DELISTED
Exact Sciences
EXAS
$14.2M 2.04%
287,300
+142,500
+98% +$5.82M
TNDM icon
19
Tandem Diabetes Care
TNDM
$1.17B
$14M 2.02%
312,500
-102,700
-25% -$4.65M
HUM icon
20
Humana
HUM
$46.7B
$13.7M 1.97%
26,750
+12,550
+88% +$6.6M
SKIN icon
21
SkinHealth Systems
SKIN
$94.9M
$12.5M 1.8%
1,376,368
-1,289,508
-48% -$13.9M
INBX
22
DELISTED
Inhibrx, Inc. Common Stock
INBX
$11.8M 1.69%
478,302
+114,400
+31% +$3.36M
INSP icon
23
Inspire Medical Systems
INSP
$1.42B
$11.6M 1.67%
46,200
-21,200
-31% -$4.52M
KROS icon
24
Keros Therapeutics
KROS
$199M
$11.2M 1.61%
233,116
+87,116
+60% +$4.07M
EPIX
25
DELISTED
ESSA Pharma
EPIX
$9.75M 1.4%
3,869,392
+1,228,853
+47% +$3.53M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Soleus Capital Management held 96 positions worth $697M, down 5.3% from $736M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $135M in Q4 2022, closing 24 positions and reducing 26 holdings. Its most notable exit was Envista, an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $8.29M.

  • Soleus Capital Management's largest Q4 2022 buy was HCA Healthcare: 34,550 shares worth $8.29M.
  • Soleus Capital Management added most to Vericel Corp in Q4 2022, an estimated $12.7M increase.
  • Soleus Capital Management's biggest Q4 2022 reduction was Illumina, cutting an estimated $27.1M.
  • Soleus Capital Management fully exited Envista in Q4 2022, selling an estimated $15.7M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $697M portfolio in Q4 2022.
  • Soleus Capital Management opened 21 new positions and closed 24 in Q4 2022.
  • Soleus Capital Management's portfolio value fell 5.3% quarter-over-quarter to $697M.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.